Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04349059
Other study ID # 2019-10465
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2023
Est. completion date December 2024

Study information

Verified date October 2023
Source Montefiore Medical Center
Contact Robert Ostfeld, MD
Phone 718-920-5197
Email ROSTFELD@montefiore.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to determine whether erectile function is impacted by dietary patterns in healthy men with normal erectile function.


Description:

Visit 1: After reviewing and signing consent, subjects will be screened for the study. Screening will consist of the following: - Complete International Index of Erectile Function (IIEF) questionnaire. - Record medical history, concomitant medications - Measure height and weight, calculate BMI - Vitals - Draw blood for total testosterone, sex hormone binding globulin and Thyroid Stimulating Hormone - Query subject regarding the presence of genital rash or lesions. Subjects will be asked, "do you have a rash or lesion on your penis or surrounding area?" If the IIEF score is abnormal, subjects will be advised to contact their primary care provider. Each subject will be contacted by phone with their blood results. If abnormal subject will be given the recommendation to contact his primary care provider. If an abnormal finding is identified during screening, such as an abnormal STOP-bang score, subject will be given the recommendation to contact his primary care provider. If the subject has no primary care provider, contact information for primary care will be given. Subjects meeting inclusion and exclusion criteria will be randomized into the study, into either Sequence One or Sequence Two. Once enrolled, subjects will be asked to not modify their dietary habits throughout the duration of the study other than during the two evenings and two full days when food is provided (see below). Sequence One: Visit 2: Subjects will return to the study center in the morning after having fasted (other than consuming water) since 11pm the night before. They will have been asked to not brush their teeth or use mouthwash and/or other breath fresheners that morning. Anthropomorphic and blood pressure and heart rate recordings will be made. Saliva will be stored for NO measurement. Blood will be drawn and stored. Urine will be collected and stored. Subjects will be taught how to use the Rigiscan™ device. Subjects will receive one plant-based dinner (food will be provided by Montefiore-Einstein Food Services.) Subjects will then leave the study center and they will consume their usual diet until 5pm. For the rest of the evening until 11pm they will consume only the dinner provided. Water will be the only beverage allowed after 5pm. Dinner should be consumed at 8:30pm EST. Subjects will text pictures of everything they consume (eat or drink) after 5pm to Dr. Ostfeld or to a study representative and s/he will have text or verbal contact with the subject at least once that evening. That night, subjects will do a Rigiscan™ assessment overnight at their home. The time the subject goes to bed and the time the subject wakes up for the day should be recorded. The subject agrees to be in bed with Rigiscan™ on (other than for emergency or needed trips to the bathroom) for at least seven hours. Visit 3 Subjects will return to the study center the morning after the Rigiscan™ assessment and bring the Rigiscan™ device with them. They will have been fasting other than drinking water since 11pm the night before. They will have been asked to not brush their teeth or use mouthwash and/or other breath fresheners that morning. Anthropomorphic and blood pressure and heart rate recordings will be taken. Saliva will be stored for NO measurement. Blood will be drawn and stored. Urine will be collected and stored. Subjects will then receive one full day of plant-based meals (food will be provided by Montefiore-Einstein Food Services.) Subjects will be encouraged to eat breakfast at the study center after the initial anthropomorphic measures are made, saliva is obtained, and blood is drawn. Subjects will text pictures of all they consume during that day to Dr. Ostfeld and/or to a study representative and s/he will have text or verbal contact with the subject at least twice during that day. Dinner should be consumed at 8:30pm, EST. Subjects will fast other than water after 11pm. That night, subjects will do a Rigiscan™ assessment overnight at their home. Black coffee and/or tea is permitted only before noon. The time the subject goes to bed and the time the subject wakes up for the day should be recorded. The subject agrees to be in bed with Rigiscan™ on (other than for emergency or needed trips to the bathroom) for at least seven hours. Visit 4 Subjects will return to the study center the morning after the Rigiscan™ assessment and bring the Rigiscan™ device with them. They will have been asked to not brush their teeth or use mouthwash and/or other breath fresheners that morning. Anthropomorphic and blood pressure and heart rate recordings will be taken. Saliva will be stored for NO measurement. Blood will be drawn and stored. Urine will be collected and stored. There will then be a washout period for 8-12 days and subjects will be instructed to return to their usual dietary habits during this washout period. Number of days of the washout period will be recorded. Visit 5 After the washout period, subjects will return to the study center in the morning after having fasted (other than consuming water) since 11pm the night before. They will have been asked to not brush their teeth or use mouthwash and/or other breath fresheners that morning. Anthropomorphic and blood pressure and heart rate recordings will be taken. Saliva will be stored for NO measurement. Blood will be drawn and stored. Urine will be collected and stored. Subjects will receive one animal-based dinner (food will be provided by Montefiore-Einstein Food Services.) Subjects will then leave the study center and they will consume their usual diet until 5pm. For the rest of the evening until 11pm they will consume only the dinner provided. Water will be the only beverage consumed after 5pm. Dinner should be consumed at 8:30pm, EST. Subjects will text pictures of all they consume (eat or drink) after 5pm to Dr. Ostfeld or to a study representative and s/he will have text or verbal contact with the subject at least once that evening. Subjects will fast other than water after 11pm. That night, subjects will do a Rigiscan™ assessment overnight at their home. The time the subject goes to bed and the time the subject wakes up for the day should be recorded. The subject agrees to be in bed with Rigiscan™ on (other than for emergency or needed trips to the bathroom) for at least seven hours. Visit 6 Subjects will return to the study center the morning after the Rigiscan™ assessment and bring the Rigiscan™ device with them. They will have been asked to not brush their teeth or use mouthwash and/or other breath fresheners that morning. Anthropomorphic and blood pressure and heart rate recordings will be taken. Saliva will be stored for NO measurement. Blood will be drawn and stored. Urine will be collected and stored. Subjects will then receive one full day of animal-based meals (food will be provided by Montefiore-Einstein Food Services.) Subjects will be encouraged to eat breakfast at the study center after the initial anthropomorphic measures are made, saliva is obtained, and blood is drawn. Subjects will text pictures of all they consume during that day to Dr. Ostfeld and/or to a study representative and s/he will have text or verbal contact with the subject at least twice during that day. Dinner should be consumed at 8:30pm, EST. Subjects will fast other than water after 11pm. That night, subjects will do a Rigiscan™ assessment overnight at their home. Black coffee and/or tea is permitted only before noon. The time the subject goes to bed and the time the subject wakes up for the day should be recorded. The subject agrees to be in bed with Rigiscan™ on (other than for emergency or needed trips to the bathroom) for at least seven hours. Visit 7 (End of Study) Subjects will return to the study center the morning after the Rigiscan™ assessment and bring the Rigiscan™ device with them. They will have been asked to not brush their teeth or use mouthwash and/or other breath fresheners that morning. Anthropomorphic and blood pressure and heart rate recordings will be taken. Saliva will be stored for NO measurement. Blood will be drawn and stored. Urine will be collected and stored. Sequence Two: Sequence Two is identical to Sequence One, except that the order of the plant-based and animal-based meals is reversed.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Subject provides written informed consent and HIPAA authorization in English before any study procedures are conducted. - Subject is taking no medical therapy other than: prn MDIs, medication(s) for anxiety, depression, and/or ADHD (these medications include, but are not limited to, SSRIs, SNRIs, Stimulants), no change in supplements if applicable. The anxiety, depression, and/or ADHD will have been controlled (per report of subject) for the last 6 months. - IIEF score greater or equal to 22 - Subject will have had penile-sexual intercourse (either vaginal or anal penetration) within 12 weeks of enrollment. - Male aged 18-35 years old - Lives within commuting distance of Montefiore Health System - Subject's significant other (if applicable) agrees to support the subject during the study - Subject agrees to photograph and share all items consumed/drunk during the dietary intervention - Subject agrees to avoid all illicit drugs, NSAIDS, and alcohol for at least two days prior to Rigiscan™ recording and on the days and nights of Rigiscan™ recording - Subject agrees to refrain from sexual activity for at least 24 hours prior to Rigiscan™ placement and to have no sexual activity on the days and nights of Rigiscan™ recording. - Subject agrees to not view, read, or otherwise consume erotic or pornographic material for 24 hours prior to both the days and nights of Rigiscan™ recording and on the days and nights of Rigiscan™ recording. - Subject agrees to not have an orgasm for 24 hours prior to both the days and nights of RigiscanTM recording and on the days and nights of Rigiscan™ recording. - Subject agrees to come to Montefiore to undergo Rigiscan™ training - Subject agrees to only consume/drink permitted food/beverages. - Subject agrees to attend all in person visits at Montefiore, to begin fasting at 11pm the night before each visit, and to undergo all blood draws/salivary/other testing. - Subject agrees to not use mouthwash or mouth rinses or intentionally spit for the entire duration of the study. Subjects will be asked to refrain from using mouthwash for at least 2 days prior to enrollment. Subject agrees to not brush his teeth in the morning of the day of each study visit. Tooth brushing is otherwise permissible. - BMI <30, BMI >=18.5, weight >110 lbs. - Subject agrees to comply with the study procedures and visits. - Subject exercises for at least 15 minutes at least two times per week - If exercise is done, subjects will exercise for the same amount of time and at a similar intensity each day of Rigiscan™ testing. Otherwise, no exercise will be performed on Rigiscan™ days. - If enrolled, subjects agree to not modify their dietary habits throughout the duration of the study other than during the two evenings and two full days when food is provided. Exclusion Criteria: - Relevant dietary allergy - Vegetarian or Vegan dietary pattern - History of an eating disorder and/or food addiction - Hypertension and or history of hypertension with or without medical treatment. Systolic blood pressure > 150mmHg and/or diastolic blood pressure >100mmHg on Visit one. Heart rate >99 on Visit one. Systolic blood pressure < 85mmHg and/or diastolic blood pressure < 50mmHg on Visit one. Heart rate < 35 on Visit one. - BMI >=30, BMI <18.5, or weight <= 110lbs - Known chronic medical disease other than non-inflammatory musculoskeletal disease, asthma, anxiety, depression, and/or ADHD. Subjects who have had changes in the dosage or type of their medication(s) for anxiety, depression, and/or ADHD within 3 months of enrollment. Subjects who have scheduled or planned medication and/or medication dose changes during the study period. These medication changes include the initiation of a new medication, discontinuation of a medication, modification of medication dose, and/or the route of administration of a medication. Subjects who are taking benzodiazepines and/or beta blockers - History of kidney disease or hyperkalemia - Subject has received an investigational drug within 30 days prior to signing consent - Erectile dysfunction - Has any condition (e.g., psychiatric illness) or situation that, in the investigator's opinion, may confound the study results, or may interfere significantly with the patient's ability to adhere with study procedures - Currently undergoing treatment for Peyronie's Disease - Abnormal Testosterone or Thyroid Stimulating Hormone level - Treated hypogonadism or hypothyroidism - Planned travel during the study - The subject is trans-gender - History of substance abuse in the last 12 months - Illicit drug use, smoking, or vaping within 4 weeks - Upper respiratory illness within two weeks on screening - If profession requires being on call, no overnight or on call duties during the study - Subject reports any communicable skin or venereal disease - Subject reports rash or lesion on the penis or surrounding area. - STOP-Bang score > 2 - Having the diagnosis of Restless Leg Syndrome. - Having insomnia as defined by: Subject with insomnia would have difficulty initiating or maintaining sleep (30 minutes or more at sleep initiation or 30 minutes or more to fall back asleep if wakes during the night). The above occurs at least 3 times per week for at least 1 month. Furthermore, there must be adequate opportunity for sleep and there must be associated morbidity (feels tired during the day). Definition based on: The International Classification of Sleep Disorders - Third Edition (ICSD-3), 2014.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Animal based diet
Food will be provided by Montefiore-Einstein Food Services
Plant based diet
Food will be provided by Montefiore-Einstein Food Services

Locations

Country Name City State
United States Montefiore Medical Center, Department of Medicine, Division of Cardiology Bronx New York

Sponsors (3)

Lead Sponsor Collaborator
Montefiore Medical Center The Greenbaum Foundation, The Purjes Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Heart rate Comparing heart rate by dietary pattern at both time points (after overnight sleep after consuming the 1 meal and after overnight sleep after consuming the 4 meals) and compared to its respective baseline in beats/minute. Definition: In regard to the following anthropometric, vital sign, and laboratory data (blood, urine, and saliva) pre-specified outcomes included in this pre-specified outcomes section, at "both time points" is defined as in the sentence above and "respective baseline" refers to either visit 2 or visit 5, as visit 2 is the baseline for one dietary arm (plant or animal) and visit 5 is the baseline for the other dietary arm (plant or animal). Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Blood Pressure Comparing blood pressure by dietary pattern at both time points and compared to its respective baseline in mmHg Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Weight Comparing weight by dietary pattern at both time points and compared to its respective baseline Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Fibrinogen Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other D-dimer Comparing it at both time points by dietary pattern and compared to its respective baseline in ng/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Total cholesterol Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other HDL cholesterol Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other HDL efflux capacity Comparing it at both time points by dietary pattern and compared to its respective baseline. Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other LDL cholesterol Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Triglyceride Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Oxidized LDL cholesterol Comparing it at both time points by dietary pattern and compared to its respective baseline in U/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Free Fatty Acids Comparing it at both time points by dietary pattern and compared to its respective baseline in micromoles Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Myeloperoxidase Comparing it at both time points by dietary pattern and compared to its respective baseline in ug/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Factor VII Comparing it at both time points by dietary pattern and compared to its respective baseline in percentage. Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other lysolecithin Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Apolipoprotein B Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Omega 3 index Comparing it at both time points by dietary pattern and compared to its respective baseline in percentage of erythrocyte fatty acid Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Lipoprotein-associated phospholipase-A2 (Lp PLA2) activity Comparing it at both time points by dietary pattern and compared to its respective baseline in nmol/min/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Lipoprotein (a) Comparing it at both time points by dietary pattern and compared to its respective baseline in nmol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Homocysteine Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other methylmalonic acid (MMA) Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Asymmetric Dimethylarginine (ADMA) Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other symmetric dimethylarginine (SDMA) Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Total testosterone Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Sex Hormone Binding Globulin Comparing it at both time points by dietary pattern and compared to its respective baseline in nmol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other cystatin C Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other remnant cholesterol particles Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other uric acid Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other interleukin 1 Comparing it at both time points by dietary pattern and compared to its respective baseline in pg/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other interleukin 6 Comparing it at both time points by dietary pattern and compared to its respective baseline in pg/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other hsCRP Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Blood Urea Nitrogen (BUN) Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Carbon Dioxide (CO2) Comparing it at both time points by dietary pattern and compared to its respective baseline in mmol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other creatinine Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other glucose Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other serum chloride Comparing it at both time points by dietary pattern and compared to its respective baseline in meq/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other serum potassium Comparing it at both time points by dietary pattern and compared to its respective baseline in meq/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other serum sodium Comparing it at both time points by dietary pattern and compared to its respective baseline in meq/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other alanine aminotransferase (ALT) Comparing it at both time points by dietary pattern and compared to its respective baseline in units/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other aspartate aminotransferase (AST) Comparing it at both time points by dietary pattern and compared to its respective baseline in units/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other estimated glomerular filtration rate (eGFR) Comparing it at both time points by dietary pattern and compared to its respective baseline in mL/min/1.73m2 Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other vitamin c Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/dL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other reduced glutathione Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other superoxide dismutase Comparing it at both time points by dietary pattern and compared to its respective baseline in ng/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other vitamin e Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other selenium Comparing it at both time points by dietary pattern and compared to its respective baseline in ng/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other malondialdehyde Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other non coding RNA Comparing it at both time points by dietary pattern and compared to its respective baseline in copies/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other micro RNA Comparing it at both time points by dietary pattern and compared to its respective baseline in copies/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Lnc RNA Comparing it at both time points by dietary pattern and compared to its respective baseline in copies/mL Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other trimethylamine-N-oxide (TMAO) Comparing it at both time points by dietary pattern and compared to its respective baseline in umol/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other phenylacetylglutamine (PAG) Comparing it at both time points by dietary pattern and compared to its respective baseline in uM (micrometers) Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Comparing urine albumin-to-creatinine ratio (UACR) Comparing it at both time points by dietary pattern and compared to its respective baseline in mg/g Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Comparing salivary nitrite level as a correlate of plasma nitric oxide (NO) level Comparing it at both time points by dietary pattern and compared to its respective baseline in micromoles/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Comparing salivary nitrate level in as a correlate of plasma nitric oxide (NO) level Comparing it at both time points by dietary pattern and compared to its respective baseline in micromoles/L Time zero (Visit 2, ~1-21 days after screen), at ~24 hours after time zero (Visit 3), at ~48 hours after time zero (Visit 4), after 8-12 day washout (Visit 5), at ~24 hours after 8-12 day washout (Visit 6), at ~48 hours after 8-12 day washout (Visit 7)
Other Percent of time =50% erect during overnight sleep after 4 meals. Total time (in minutes) when penile rigidity is =50% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). During overnight sleep directly after consuming the 4 meals.
Other Percent of time =50% erect during overnight sleep after 1 meal. Total time (in minutes) when penile rigidity is =50% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). During overnight sleep directly after consuming the 1 meal.
Other Erection events per hour during overnight sleep after 1 meal. Total number of erection events lasting =5 minutes and with =70% rigidity at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Events/hour. During overnight sleep directly after consuming the 1 meal.
Other Tumescence events per hour during overnight sleep after 1 meal. Total number of tumescence events lasting =5 minutes and when penile circumference increases by =2cm at both the tip and the base of the penis compared to their respective baselines as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Tumescence events/hour. During overnight sleep directly after consuming the 1 meal.
Other Percent of time =70% erect during overnight sleep after 4 meals versus after 1 meal by dietary pattern. This outcome will evaluate whether a difference is present in the percent of time =70% erect during overnight sleep (as defined in outcomes above) directly after consuming the 4 meals versus directly after consuming the 1 meal by dietary pattern, for each dietary pattern. (e.g. is there a greater percentage of time =70% erect on the second night versus the first night when consuming the plant-based diet?). During overnight sleep directly after consuming the 4 meals versus overnight sleep directly after consuming the 1 meal by dietary pattern, for each dietary pattern.
Other Percent of time =50% erect during overnight sleep after 4 meals versus after 1 meal by dietary pattern. This outcome will evaluate whether a difference is present in the percent of time =50% erect during overnight sleep (as defined in outcomes above) directly after consuming the 4 meals versus directly after consuming the 1 meal by dietary pattern, for each dietary pattern. (e.g. is there a greater percentage of time =50% erect on the second night versus the first night when consuming the plant-based diet?). During overnight sleep directly after consuming the 4 meals versus overnight sleep directly after consuming the 1 meal by dietary pattern, for each dietary pattern.
Other Tumescence events per hour during overnight sleep after 4 meals versus after 1 meal by dietary pattern. This outcome will evaluate whether a difference is present in the total number of tumescence events per hour (as defined in outcomes above) directly after consuming the 4 meals versus directly after consuming the 1 meal by dietary pattern, for each dietary pattern. (e.g. is there a greater of tumescence events per hour on the second night versus the first night when consuming the plant-based diet?). During overnight sleep directly after consuming the 4 meals versus overnight sleep directly after consuming the 1 meal by dietary pattern, for each dietary pattern.
Primary Percent of time =70% erect during overnight sleep after 4 meals. Total time (in minutes) when penile rigidity is = 70% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). During overnight sleep directly after consuming the 4 meals.
Secondary Percent of time =70% erect during overnight sleep after 1 meal. Total time (in minutes) when penile rigidity is =70% at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). During overnight sleep directly after consuming the 1 meal.
Secondary Erection events per hour during overnight sleep after 4 meals. Total number of erection events lasting =5 minutes and with =70% rigidity at both the tip and the base of the penis as measured by Rigiscan™ during overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Events/hour. During overnight sleep directly after consuming the 4 meals.
Secondary Tumescence events per hour during overnight sleep after 4 meals. Total number of tumescence events lasting =5 minutes and when penile circumference increases by =2cm at both the tip and the base of the penis compared to their respective baselines as measured by Rigiscan™ during overnight sleep, divided by the total time (in minutes) of overnight sleep. Overnight sleep is defined as the time in minutes from the onset of the first nocturnal erection to the end of the last nocturnal erection (as measured by Rigiscan™). This result will be reported as Tumescence events/hour During overnight sleep directly after consuming the 4 meals.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05366504 - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment Phase 2/Phase 3
Recruiting NCT02573805 - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Recruiting NCT02225548 - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Phase 4
Completed NCT02587988 - Trial to Evaluate the Efficacy and Safety of HCP1302 Phase 3
Completed NCT01937871 - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) Phase 3
Completed NCT02945462 - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED) Phase 1
Completed NCT01698684 - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Phase 4
Not yet recruiting NCT01321489 - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies Phase 3
Completed NCT01230541 - Effect of Udenafil on Spermatogenesis Phase 1
Terminated NCT01262833 - Pudendal Assessment in Erectile Dysfunction N/A
Completed NCT02226237 - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy N/A
Completed NCT01037218 - Treatment of Erectile Dysfunction II Phase 3
Completed NCT01037244 - Treatment of Erectile Dysfunction I Phase 3
Recruiting NCT00313898 - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Phase 4
Completed NCT00667979 - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Phase 4
Completed NCT00421083 - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury Phase 3
Completed NCT00663728 - Assessment of Duration of Erection With Vardenafil 10 mg Phase 4